| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00078-0438-15 | 00078-0438 | Imatinib Mesylate | Gleevec | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 15, 2001 | May 31, 2017 | In Use |
| 63459-0177-14 | 63459-0177 | Omacetaxine Mepesuccinate | Synribo | 3.5 mg/mL | Chemotherapy | Plant Alkaloid | BCR-ABL | Subcutaneous | Nov 19, 2012 | Apr 30, 2024 | No Longer Used |
| 24338-0155-01 | 24338-0155 | Nilotinib | DANZITEN | 95.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 30, 2024 | In Use | |
| 69097-0031-73 | 69097-0031 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 72819-0185-09 | 72819-0185 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2022 | In Use | |
| 69097-0030-63 | 69097-0030 | Nilotinib | Nilotinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 47335-0472-88 | 47335-0472 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 13668-0710-57 | 13668-0710 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 16, 2025 | In Use | |
| 62332-0689-30 | 62332-0689 | DASATINIB | DASATINIB | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 11, 2025 | In Use | |
| 72606-0557-01 | 72606-0557 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 6, 2019 | In Use | |
| 59651-0545-15 | 59651-0545 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 50268-0427-12 | 50268-0427 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 24, 2017 | In Use | |
| 69097-0577-74 | 69097-0577 | nilotinib | NILCEYA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 68001-0490-05 | 68001-0490 | imatinib mesylate | imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 26, 2021 | In Use | |
| 31722-0779-33 | 31722-0779 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 19, 2025 | In Use | |
| 00054-0248-12 | 00054-0248 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
| 00069-0135-01 | 00069-0135 | Bosutinib monohydrate, Bosutinib | Bosulif | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
| 60505-2901-00 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 60505-3801-05 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 60505-3802-00 | 60505-3802 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use | |
| 60505-2901-09 | 60505-2901 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 68382-0244-05 | 68382-0244 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 62135-0658-90 | 62135-0658 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 28, 2024 | In Use | |
| 43598-0344-30 | 43598-0344 | Imatinib | Imatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 13, 2018 | In Use | |
| 70709-0152-50 | 70709-0152 | dasatinib | PHYRAGO | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 22, 2025 | In Use |
Found 12250 results — Export these results
Home